Grand Pharmaceutical Group Limited (0512.HK) is a technologically innovative international pharmaceutical enterprise. Its core businesses cover three major areas, namely pharmaceutical technology, nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology and biotechnology. Based on the pharmaceutical and biotechnology industries, the Group will focus on the needs of patients, and take technological innovation as the driving force. In response to the unmet clinical needs, the Group will increase its investment in global innovative products and advanced technologies, enrich and improve its product pipelines, consolidate and strengthen its industrial chain layout, and fully leverage the Group’s industrial strengths and R&D capabilities to provide more advanced and diverse treatment solutions to patients worldwide.
With unremitting efforts in recent years, the Group has laid a more solid foundation for development, consolidated its operation scale, gradually optimized its business structure, continued to improve its operation mode, accelerated its pace of transformation and upgrading, and made various achievements in innovative layout. The Group’s profitability continues to improve and help facilitate R&D and innovation; its good ability in mergers and acquisitions and integration continues to consolidate the scale of development; the integration of raw materials and preparations improves the structure of the industrial chain; and the diversification of business and entities has effectively enhanced the comprehensive advantages.
“Maintain stable growth, strive in innovation and strategic planning”, upon the principles of meeting the needs of patients, adapting to market development and insisting on technological innovation as well as the development concept of “comprehensive strengths, innovation leading and global expansion” and the strategy of “dual-wheel driving development of independent R&D, global expansion and dual-cycle operation”, the Group has formed a new pattern of domestic and international cycles that synergize with each other, and is committed to becoming an international pharmaceutical company of technological innovation, delivering on its promises for doctors and patients, and making significant contribution to the society.